Skip to main navigation

Skip to Content

Overview
Stock Information
News & Events
Financials
- SEC Filings
- Quarterly Results
Governance
- Governance Highlights
- Committee Composition
Investor Resources

News Releases

2018 Investor Presentation

Year

Jul 20, 2023

HARMONY BIOSCIENCES ANNOUNCES PLANS TO INITIATE PHASE 3 REGISTRATIONAL STUDY OF PITOLISANT IN PRADER-WILLI SYNDROME FOLLOWING POSITIVE END-OF-PHASE 2 MEETING WITH THE U.S. FOOD AND DRUG ADMINISTRATION

Jul 18, 2023

HARMONY BIOSCIENCES TO REPORT SECOND QUARTER 2023 FINANCIAL RESULTS ON AUGUST 1, 2023

Jun 06, 2023

HARMONY BIOSCIENCES ANNOUNCES POSITIVE PHASE 2 SIGNAL DETECTION STUDY EVALUATING PITOLISANT FOR EXCESSIVE DAYTIME SLEEPINESS IN PRADER-WILLI SYNDROME AT SLEEP 2023

May 30, 2023

HARMONY BIOSCIENCES TO PARTICIPATE IN GOLDMAN SACHS 44th ANNUAL GLOBAL HEALTHCARE CONFERENCE

May 25, 2023

HARMONY BIOSCIENCES COMPLETES ENROLLMENT OF PHASE 3 REGISTRATIONAL INTUNE STUDY IN IDIOPATHIC HYPERSOMNIA

May 10, 2023

HARMONY BIOSCIENCES TO PRESENT NEW WAKIX® (PITOLISANT) SAFETY AND EFFICACY DATA AT SLEEP 2023 ANNUAL MEETING

May 02, 2023

Harmony Biosciences Reports First Quarter 2023 Financial Results and Business Updates

Apr 24, 2023

HARMONY BIOSCIENCES ANNOUNCES JEFFREY M. DAYNO, M.D. APPOINTED PRESIDENT & CHIEF EXECUTIVE OFFICER

Apr 20, 2023

HARMONY BIOSCIENCES TO REPORT FIRST QUARTER 2023 FINANCIAL RESULTS ON MAY 2, 2023

Mar 29, 2023

HARMONY BIOSCIENCES ANNOUNCES ACCELERATED TIMELINE FOR PHASE 3 INTUNE STUDY IN IDIOPATHIC HYPERSOMNIA

Pagination

First page
Previous page
Page 1
Current page 2
Page 3
Next page
Last page

Displaying 11 - 20 of 26

Site - Shareholder Tools

Copyright © 2023 Harmony Biosciences All rights reserved.

Facebook
Twitter
LinkedIn
Google+